ICICI Securities has issued a buy rating on Sagility India with a target price of ₹66 in its research report dated March 27, 2026. According to the brokerage report, the recommendation is based on a 22x one year forward PE multiple valuation methodology. The stock recommendation comes as part of ICICI Securities' broader positive outlook on health technology plays in the US healthcare sector.
Sagility India hosted its first analyst meet on March 25, 2026, where the company highlighted AI as a key growth driver integrated across most of its solutions and platforms. As reported by ICICI Securities, the company emphasized that the complicated nature of the US healthcare industry, along with a low-20s outsourcing share, creates a deep moat for Sagility. This competitive advantage is evidenced by the company's 97% client retention rate and 18-year average client tenure.
The analyst meet revealed significant growth opportunities in the healthcare sector, with MLR (Medical Loss Ratio), appeals and clinical services identified as fast-growing new avenues. According to ICICI Securities, these segments present an opportunity worth USD 200-320 billion. The company also highlighted a shift towards outcome-based pricing models due to AI integration, which is expected to expand the overall scope of work for healthcare service providers.
Sagility India maintained its growth and margin guidance during the analyst meet, demonstrating confidence in its business trajectory. ICICI Securities remains positive on health technology plays including Sagility, Indegene and IKS Health, citing the defensive nature of the US healthcare industry. The brokerage maintains its bullish stance on these healthcare technology stocks given the sector's resilience and growth potential.
